Recent Finacing
Recent Raise
Camallergy, based in Cambridge, develops CA002, a second-generation oral peanut immunotherapy designed to provide bite-proof protection within 14 weeks and operates Europe’s only cGMP-certified peanut-immunotherapy manufacturing facility.
